Table 2.
Unadjusted univariate analysis
| Outcomes | Autologous | NST/RIC | P-value | ||
|---|---|---|---|---|---|
| N | Prob (95% CI) | N | Prob (95% CI) | ||
| Engraftment | |||||
| ANC ≥ 500/mm3 | |||||
| @ 28 days | 137 | 96 (92–98) | 152 | 96 (93–98) | 0.999 |
| Platelets ≥ 20 × 109/L | |||||
| @ 28 days | 137 | 90 (84–94) | 152 | 77 (70–83) | 0.007* |
| @ 60 days | 137 | 93 (89–97) | 152 | 84 (78–89) | 0.009* |
| Acute graft-versus-host disease | |||||
| @ 30 days | NA | 152 | 21 (15–28) | -- | |
| @ 60 days | NA | 35 (28–43) | -- | ||
| Chronic graft-versus-host disease | |||||
| @ 12 months | NA | 152 | 42 (34–50) | -- | |
| @ 36 months | NA | 44 (36–52) | -- | ||
| Relapse/Progression | |||||
| @ 12 months | 137 | 53 (44–61) | 152 | 72 (64–79) | <0.001* |
| @ 36 months | 137 | 84 (76–90) | 80 (73–86) | 0.655 | |
| @ 60 months | 137 | 91 (85–96) | 83 (77–89) | 0.046* | |
| Non-relapse mortality | |||||
| @ 12 months | 137 | 2 (1–5) | 152 | 13 ( 8–19) | <0.001* |
| @ 36 months | 4 (2–8) | 14 ( 9–20) | <0.001* | ||
| @ 60 months | 4 (2–8) | 15 (10–21) | <0.001* | ||
| Progression free survival | |||||
| @ 12 months | 137 | 45 (37–54) | 152 | 15 (10–21) | <0.001* |
| @ 36 months | 12 (7–19) | 6 ( 3–10) | 0.038* | ||
| @ 60 months | 4 (1–11) | 2 (<1–5) | 0.235 | ||
| Overall survival | |||||
| @ 100 days | 137 | 97 (91–98) | 152 | 77 (69–83) | <0.001* |
| @ 12 months | 82 (75–88) | 51 (42–58) | <0.001* | ||
| @ 36 months | 46 (37–55) | 20 (14–27) | <0.001* | ||
| @ 60 months | 29 (20–40) | 9 ( 5–15) | <0.001* | ||
*
significant difference
NST/RIC = non-myeloablative stem cell transplant/reduced intensity conditioning